Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational study

20260 citationsJournal Articlegold Open Access

Authors

Stella Chen · Beth Israel Deaconess Medical Center

Bruna Galvao de O. Wafae · Beth Israel Deaconess Medical Center

Sydney Look-Why · Beth Israel Deaconess Medical Center

T. Otto · Beth Israel Deaconess Medical Center

C. Snyder · Beth Israel Deaconess Medical Center

William Sweet · Beth Israel Deaconess Medical Center

Nazrin Ashina

Abstract

Higher ADA concentrations and lower drug clearance are associated with better clinical outcomes in HS. ROC analysis identified 10.7 μg/mL (ADA concentration) and 0.5 L/day (clearance) as optimal cut-off values to differentiate low from partial/high responders. These findings suggest that therapeutic drug monitoring may help optimize ADA therapy in HS.

Topics & Keywords

Hidradenitis Suppurativa and Treatments Acne and Rosacea Treatments and Effects Anorectal Disease Treatments and Outcomes

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: Frontiers in Immunology

Volume 17, pp. 1760206-1760206

DOI: 10.3389/fimmu.2026.1760206

Field-Weighted Citation Impact: 0.00